Mavacamten clinical trials
Mavacamten is named as an intervention in 16 current clinical trials in our USA, UK, China, Germany, France, Spain, Canada, Australia, Japan, Ireland, Italy, Switzerland, Poland, Austria, Czechia, India and South Korea registers. 8 are recruiting patients now. The most common phase is Observational. The sponsor with the most trials is Bristol-Myers Squibb (14). The most-studied condition is Obstructive Hypertrophic Cardiomyopathy (oHCM).
Where Mavacamten is approved
All regulators →Of the three regulators tracked here, the first to approve Mavacamten was the US, on 28 Apr 2022. It is approved in 3 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Mavacamten patents and exclusivity
Expiry tracker →Protections still running for marketed products containing Mavacamten, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
- 2 listed patents; the last listed expires 28 Apr 2036 (US RE50050).
- Latest patent on the drug substance itself: 28 Apr 2036 (US RE50050).
- Exclusivity ODE-398: Orphan drug exclusivity: treatment of adults with symptomatic new york heart association (nyha) class II-III obstructive hypertrophic cardi…, until 28 Apr 2029.
- Exclusivity NCE: New chemical entity, until 28 Apr 2027.
Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
What health systems spend on Mavacamten
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Mavacamten works
All drug targets →- Cardiac myosin inhibitor InhibitorTarget: Cardiac myosinChEMBL only
- Hypertensive disorderPhase 3
- Heart failurePhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4297517, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 11265, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
NICE appraisals of Mavacamten
All NICE appraisals →NICE, which decides whether the NHS in England should fund new medicines, has published 1 technology appraisal of Mavacamten. 1 is current, and 1 of it recommends it for at least some patients.
| Appraisal | NICE recommendation | Published | Status |
|---|---|---|---|
| Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy NICE TA913 | Optimised | 6 Sep 2023 | Current |
NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Patient leaflets for Mavacamten
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 4 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- EUEuropean Union: CamzyosEMA product information: package leaflet and summary of product characteristics in every EU language.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Mavacamten
- ChEMBL
- CHEMBL4297517
- DrugBank
- DB14921
- PubChem CID
- 117761397
- CAS number
- 1642288-47-8
- FDA UNII
- QX45B99R3J
- Wikidata
- Q105337531
- Wikipedia
- Mavacamten
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Mavacamten
16 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Mavacamten across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
4 single-substance products containing Mavacamten on the HPRA medicines list.
- Camzyos 10 mg Capsule hardBristol-Myers Squibb Pharma EEIG · EU/1/23/1716/005-006/011
- Camzyos 15 mg Capsule hardBristol-Myers Squibb Pharma EEIG · EU/1/23/1716/007-008/012
- Camzyos 2.5 mg Capsule hardBristol-Myers Squibb Pharma EEIG · EU/1/23/1716/001-002/009
- Camzyos 5 mg Capsule hardBristol-Myers Squibb Pharma EEIG · EU/1/23/1716/003-004/010
Supply shortages
No entry for Mavacamten in the EMA, FDA or German BfArM shortage lists we track.
Conditions studied with Mavacamten
11 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Bristol-Myers Squibb | 14 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
| Xu Liu | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Mavacamten trials
How many clinical trials are testing Mavacamten?
16 current trials in our USA, UK, China, Germany, France, Spain, Canada, Australia, Japan, Ireland, Italy, Switzerland, Poland, Austria, Czechia, India and South Korea registers name Mavacamten (also registered as BMS-986427) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Mavacamten trials recruiting patients?
Yes. 8 of the 16 trials are recruiting: 3 with sites in USA, 2 with sites in UK, 1 with sites in China, 1 with sites in Germany, 1 with sites in France, 1 with sites in Spain, 2 with sites in Japan, 1 with sites in Poland, 1 with sites in Austria, 1 with sites in Czechia and 1 with sites in South Korea. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Mavacamten clinical trials?
Bristol-Myers Squibb (14), Second Affiliated Hospital, Zhejiang University, School of Medicine (1) and Xu Liu (1). The number in brackets is how many trials each organisation leads.
Are there Mavacamten clinical trials in Ireland?
Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Is Mavacamten licensed in Ireland?
Yes. The HPRA medicines list includes 4 single-substance products containing Mavacamten, for example Camzyos 10 mg Capsule hard (Bristol-Myers Squibb Pharma EEIG). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Mavacamten shortage?
Not in the lists we track: Mavacamten has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Mavacamten works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Mavacamten works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Mavacamten (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.